LCK - Wiki-MPM

Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
CSF2RB	colony stimulating factor 2 receptor subunit beta	Interleukin-3, Interleukin-5 and GM-CSF signaling Interleukin-3, Interleukin-5 and GM-CSF signaling RAF/MAP kinase cascade Surfactant metabolism Defective CSF2RB causes SMDP5 Defective CSF2RA causes SMDP4 Interleukin receptor SHC signaling	Sargramostim NPI 32101 Resatorvid
FYN	FYN proto-oncogene, Src family tyrosine kinase	GPVI-mediated activation cascade Signaling by ERBB2 PIP3 activates AKT signaling Signaling by SCF-KIT Signaling by SCF-KIT Regulation of KIT signaling Nef and signal transduction Cell surface interactions at the vascular wall FCGR activation PECAM1 interactions Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling DAP12 signaling EPH-Ephrin signaling Role of LAT2/NTAL/LAB on calcium mobilization Nephrin family interactions Nephrin family interactions NCAM signaling for neurite out-growth NCAM signaling for neurite out-growth CD28 co-stimulation CD28 dependent PI3K/Akt signaling CD28 dependent Vav1 pathway CTLA4 inhibitory signaling EPHB-mediated forward signaling EPHB-mediated forward signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse Ephrin signaling Ephrin signaling EPH-ephrin mediated repulsion of cells Sema3A PAK dependent Axon repulsion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion CRMPs in Sema3A signaling CRMPs in Sema3A signaling VEGFA-VEGFR2 Pathway Dectin-2 family CD209 (DC-SIGN) signaling RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Platelet Adhesion to exposed collagen Reelin signalling pathway Regulation of signaling by CBL Regulation of signaling by CBL FCGR3A-mediated IL10 synthesis FCGR3A-mediated phagocytosis Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants FLT3 signaling through SRC family kinases Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Dasatinib Triglyme Fostamatinib
NFKBIA	NFKB inhibitor alpha	Activation of NF-kappaB in B cells RIP-mediated NFkB activation via ZBP1 Downstream TCR signaling NF-kB is activated and signals survival FCERI mediated NF-kB activation TAK1 activates NFkB by phosphorylation and activation of IKKs complex SUMOylation of immune response proteins IkBA variant leads to EDA-ID CLEC7A (Dectin-1) signaling Ub-specific processing proteases Interleukin-1 signaling TRAF6 mediated NF-kB activation	Acetylsalicylic acid Bardoxolone methyl Astaxanthin	Ectodermal dysplasia associated immunodeficiency (EDA-ID), including the following two diseases: NF-kappa-B essential modulator (NEMO) defect; Inhibitor of kappa-B (I-kappa-B) defect Hodgkin lymphoma
ACP1	acid phosphatase 1		Adenine 4-Nitrophenyl Phosphate
AXL	AXL receptor tyrosine kinase	VEGFA-VEGFR2 Pathway	Fostamatinib Gilteritinib
CD2	CD2 molecule	Cell surface interactions at the vascular wall	Alefacept Siplizumab
CD3E	CD3e molecule	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Downstream TCR signaling Phosphorylation of CD3 and TCR zeta chains Translocation of ZAP-70 to Immunological synapse Generation of second messenger molecules PD-1 signaling	Muromonab Catumaxomab	T-B+Severe combined immunodeficiencies (SCIDs), including the following eight diseases: X-linked SCID; Janus kinase-3 (Jak3) deficiency; IL-7 receptor alpha (IL7R alpha) deficiency; IL-2 receptor alpha (IL2R alpha) deficiency; CD45 deficiency; CD3 deficiency; Winged Helix Nude (WHN) deficiency; Immunodeficiency with thynoma
CD44	CD44 molecule (Indian blood group)	Degradation of the extracellular matrix Cell surface interactions at the vascular wall Integrin cell surface interactions Hyaluronan uptake and degradation Neutrophil degranulation Interferon gamma signaling	Bivatuzumab Hyaluronic acid	Gastric cancer
CDC42	cell division cycle 42	GPVI-mediated activation cascade EGFR downregulation Rho GTPase cycle Regulation of actin dynamics for phagocytic cup formation Regulation of actin dynamics for phagocytic cup formation CD28 dependent Vav1 pathway EPHB-mediated forward signaling EPHB-mediated forward signaling DCC mediated attractive signaling Inactivation of CDC42 and RAC1 VEGFA-VEGFR2 Pathway Myogenesis Myogenesis RHO GTPases activate KTN1 RHO GTPases activate IQGAPs RHO GTPases activate PAKs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate Formins RHO GTPases Activate Formins MAPK6/MAPK4 signaling Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation G beta:gamma signalling through CDC42 FCGR3A-mediated phagocytosis FCGR3A-mediated phagocytosis Factors involved in megakaryocyte development and platelet production	Aminophosphonic acid-guanylate ester Guanosine-5'-Diphosphate
CSNK2B	casein kinase 2 beta	Synthesis of PC WNT mediated activation of DVL Condensation of Prometaphase Chromosomes Signal transduction by L1 Neutrophil degranulation Regulation of TP53 Activity through Phosphorylation Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding Receptor Mediated Mitophagy RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known Regulation of PTEN stability and activity	ATP Quercetin
CTDSP1	CTD small phosphatase 1		Aspartate beryllium trifluoride Citric acid
CTLA4	cytotoxic T-lymphocyte associated protein 4	CTLA4 inhibitory signaling RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)	Ipilimumab Tremelimumab	Type I diabetes mellitus Graves' disease Allograft rejection Hashimoto's thyroiditis
IKBKG	inhibitor of nuclear factor kappa B kinase regulatory subunit gamma	Activation of NF-kappaB in B cells Activation of NF-kappaB in B cells ER-Phagosome pathway NOD1/2 Signaling Pathway TICAM1, RIP1-mediated IKK complex recruitment RIP-mediated NFkB activation via ZBP1 Downstream TCR signaling FCERI mediated NF-kB activation TAK1 activates NFkB by phosphorylation and activation of IKKs complex activated TAK1 mediates p38 MAPK activation JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 SUMOylation of immune response proteins Regulation of TNFR1 signaling TNFR1-induced NFkappaB signaling pathway IKBKB deficiency causes SCID IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) IkBA variant leads to EDA-ID CLEC7A (Dectin-1) signaling MAP3K8 (TPL2)-dependent MAPK1/3 activation Ub-specific processing proteases Ovarian tumor domain proteases Interleukin-1 signaling TRAF6 mediated NF-kB activation NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 IRAK1 recruits IKK complex IKK complex recruitment mediated by RIP1 IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation	AGRO100 Tarenflurbil	Ectodermal dysplasia associated immunodeficiency (EDA-ID), including the following two diseases: NF-kappa-B essential modulator (NEMO) defect; Inhibitor of kappa-B (I-kappa-B) defect Incontinentia pigmenti Osteoporosis, lymphedema, anhydrotic ectodermal dysplasia with immunodeficiency (OLEDAID); Ectodermal dysplasia, anhidrotic, with immunodeficiency, osteopetrosis, and lymphedema
PLD2	phospholipase D2	Synthesis of PG Synthesis of PA Role of phospholipids in phagocytosis	Choline Choline salicylate
ZAP70	zeta chain of T cell receptor associated protein kinase 70	Translocation of ZAP-70 to Immunological synapse Generation of second messenger molecules	Staurosporine Fostamatinib	Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
CD247	CD247 molecule		Muromonab
CD55	CD55 molecule (Cromer blood group)	Class B/2 (Secretin family receptors) Neutrophil degranulation COPI-mediated anterograde transport Regulation of Complement cascade	Chloramphenicol	Complement regulatory protein defects, including the following six diseases: C1 inhibitor deficiency (hereditary angioedema); C4 binding protein alpha deficiency; C4 binding protein beta deficiency; Factor I deficiency; Decay-accelerating factor (CD55) deficiency; CD59 deficiency
CD79B	CD79b molecule	CD22 mediated BCR regulation Antigen activates B Cell Receptor (BCR) leading to generation of second messengers Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Polatuzumab vedotin	Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8
DAPP1	dual adaptor of phosphotyrosine and 3-phosphoinositides 1	Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	Inositol 1,3,4,5-Tetrakisphosphate
ERBB3	erb-b2 receptor tyrosine kinase 3		Tucatinib	Lethal congenital contractural syndrome (LCCS) Type I diabetes mellitus

Search Results for: LCK